Olema Oncology (NASDAQ: OLMA) announced preliminary results from its phase 1 study of OP-3136, an experimental cancer treatment targeting the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE